The global urea cycle disorders treatment market includes various therapies such as amino acid supplements, sodium phenylbutyrate, glycerol phenylbutyrate, sodium benzoate, low protein diet, carglumic acid, etc. for the treatment of the inherited disorder such as urea cycle disorders, which affects various enzymes taking part in the urea cycle pathway in the human system. The urea cycle disorders are classified according to the deficiencies observed in different enzymes of the urea cycle such as OTC – ornithine transcarbamylase, ASD – argininosuccinic acid synthetase (citrullinemia), AG – Arginase, ALD – argininosuccinase acid lyase (argininosuccinic aciduria), CPS – carbamoyl phosphate synthetase, and NAGS – N-acetylglutamate synthetase.

Market Dynamics

Market players are focused on adopting different business strategies such as mergers and acquisitions in order to expand their offerings in the market.

For instance, in February 2017, Mead Johnson Nutrition Company (MJN) announced its merger with Reckitt Benckiser Group plc (RB).  Mead Johnson, now a division of RB, added its globally-recognized brands, including Enfa and Nutramigen, which are used in dietary management of urea cycle disorder, to RB’s consumer health portfolio, thus strengthening its position globally.

Moreover, For Instance, In October 2017, Lucane Pharma SA was acquired by the Eurocept Pharmaceuticals, a company developing, distributing, and marketing of medicinal products in therapeutic areas such as anesthesia, oncology, immunology, and neurology. This acquisition has aided Eurocept Pharmaceuticals to invest in research and development of medicines for rare metabolic diseases such as urea cycle disorders.

Furthermore, Key players focused on inorganic strategies such as distribution agreements in order to strengthen their presence in the market.

For Instance, In 2016, Horizon Pharma plc and Swedish Orphan Biovitrum AB (publ) (Sobi), a biotechnological company in Sweden, announced the distribution agreement for the distribution of Ravicti in European countries including the U.K,. Germany, Italy, France, and Spain.

Key features of the study

• This report provides in-depth analysis of the global urea cycle disorders treatment market, provides market size (US$ Mn) and compound annual growth rate (CAGR) (%) for the forecast period (2026–2033)
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market. It provides valuable insights about market drivers, restraints, opportunities, country outlook, and competitive strategies adopted by the leading players.
• It profiles leading players in the global urea cycle disorders treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and future plans
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions with respect to their future market expansion and marketing tactics
• The global urea cycle disorders treatment market report caters to various stakeholders in this industry, including investors, product developers and manufacturers, distributors, healthcare organizations, research institutes, new entrants, and financial analysts
• Stakeholders would greatly benefit in decision-making through various strategy matrices used in analyzing the global urea cycle disorders treatment market

Market Segmentation

• By Treatment Type (Revenue, USD Mn, 2021-2033)
  • Amino Acid Supplements
  • Sodium Phenylbutyrate
  • Glycerol Phenylbutyrate
  • Sodium Benzoate
  • Others (Low Protein Diet, Carglumic acid, etc.)
• By Enzyme Deficiency Type (Revenue, USD Mn, 2021-2033)
  • OTC – Ornithine Transcarbamylase
  • AS – Argininosuccinate Synthetase (citrullinemia)
  • AG – Arginase
  • AL – Argininosuccinate Lyase
  • CPS1 – Carbamoyl Phosphate Synthase
  • NAGS – N-acetylglutamate Synthase
• By Route of Administration (Revenue, USD Mn, 2021-2033)
  • Oral
  • Injectable
• By Distribution Channel (Revenue, USD Mn, 2021-2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region (Revenue, USD Mn, 2021-2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa
• Key Players
  • Bausch Health Companies, Inc.
  • Recordati Rare Diseases Inc.
  • Lucane Pharma SA
  • Acer Therapeutics
  • Ultragenyx Pharmaceutical Inc.
  • Aeglea BioTherapeutics
  • Arcturus Therapeutics Holdings Inc.
  • Orpharma Pty Ltd.
  • Selecta Biosciences, Inc.
  • Abbott Laboratories
  • NESTLE S.A.
  • DANONE S.A.
  • Mead Johnson & Company, LLC